Alaunos Therapeutics
TCRT
136 hedge funds and large institutions have $290M invested in Alaunos Therapeutics in 2016 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 17 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 34
0.27% more ownership
Funds ownership: 0% → 0.27% (+0.27%)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
3% less funds holding
Funds holding: 140 → 136 (-4)
5% less capital invested
Capital invested by funds: $306M → $290M (-$16.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
34% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $17.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.21M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.24M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.27M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.18M |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.62M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.64M |
| 3 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$2.95M |
| 4 |
Renaissance Technologies
New York
|
-$1.78M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.67M |
TCRT Hedge Fund Activity: Q4 2016 in Review
136 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2016, worth a combined $290M — down 5.3% from $306M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TCRT and 16 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 42 added.
The largest buyer was Invesco, adding an estimated $6.21M. The largest seller was State Street, cutting an estimated $4.62M.
- 136 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2016, down from 140 in Q3 2016.
- Funds reported $290M of Alaunos Therapeutics stock for Q4 2016, down 5.3% quarter-over-quarter.
- 16 funds opened new Alaunos Therapeutics positions in Q4 2016 and 17 closed out, a net change of -1 holder.
- The largest Alaunos Therapeutics buyer in Q4 2016 was Invesco, an estimated $6.21M added.
- The largest Alaunos Therapeutics seller in Q4 2016 was State Street, an estimated $4.62M sold.
Based on aggregated 13F filings for Q4 2016.